Contact Us:949-229-0094Test@Btgenomics.com

How to Order The Test

The BT-Reveal Early Pancreatic Cancer Test is specifically designed for individuals with an elevated risk to develop pancreatic cancer. The test can only be ordered by a doctor.

Doctors can order the test for their patients by signing up in our secure online portal called My Gene Scan or by emailing us at test@BTGenomics.com

All tests require that a BT-Reveal Test Requisition Form is filled out by a doctor or healthcare provider. Within the form, there are a number of ICD-10 diagnostic codes that a doctor can select for their patient.

There are 3 main categories for the use of this test. First, as an essential and safe tool for periodic pancreatic cancer surveillance in high-risk individuals, second as a complementary test in GI endoscopy centers who are confronted with indeterminate imaging results or pancreatic cysts that may or may not be malignant, and third, when patients present with potential clinical indications for pancreatic cancer, including pancreatitis, non-specific back or stomach pain, jaundice, or unintended weight loss.

If you are patient who may be at risk or who fits into one of the 3 categories listed above and is interested in getting test, you can encourage your doctor or healthcare provider to sign-up as a provider of the test. The sign up is easy and BREAKTHROUGH GENOMICS team is available to provide support and any additional information to you, your doctor, or healthcare provider. Don’t hesitate to contact us via email at test@BTGenomics.com or by phone at 949-229-0094.

Additional Information

BTG_PancCan_ReportGraphic

The BT-Reveal Early Pancreatic Cancer Test is intended for use as a screening tool for at-risk individuals. A positive result does not guarantee the individual has cancer. For all positive results, additional follow-up imaging and other confirmatory tests are recommended. Common follow up testing includes CT Scans, MRI’s, Endoscopic Ultrasounds, or ERCP tests.

rsz_1rsz_1rsz_btg_pancreaticcancer_logo3

Breakthrough Genomics’s clinical laboratory in Irvine, California is certified in the U.S. under the Clinical Laboratory Improvements Amendments (CLIA) and by the College of American Pathologists (CAP) to perform high complexity clinical genomic tests. The BT-Reveal Early Pancreatic Cancer Test only requires a 10ml tube of blood that can be stored and transported at room temperature. The test is currently being offered as a Laboratory Developed Test (LDT) and as such surpasses the lab’s requirements needed to be able to safely provide the test to at-risk individuals.

2 Hughes #100, Irvine, CA 92618

Breakthrough Genomics